March 18, 2021
Pyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates
— Pyxis expands developmental capabilities with license to two ADC programs and ADC technology platform toolkit developed by Pfizer — CAMBRIDGE, Mass., March 18, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced that it has entered into a worldwide license agreement with Pfizer Inc. (NYSE:PFE) for the development and commercialization of two antibody-drug
